Previous 10 | Next 10 |
home / stock / invvy / invvy news
Indivior PLC ADR press release ( OTCPK:INVVY ): Q4 Non-GAAP EPS of $0.27. Revenue of $241M (+8.6% Y/Y). Guidance: TotalFY2023expectedNRrangeof$950Mto$1,020M(+9%vs.FY2022atthemid-point),reflectingcontinued strongSUBLOCADEandPERSERISgrowthandacceleratedshareerosionforUSSUBOXONEF...
FY 2022 Financial Results Announced PR Newswire SLOUGH, England and RICHMOND, Va. , Feb. 16, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at ww...
Summary Drug addiction is on the rise but so are treatments for it, like those provided by Indivior for opioid usage. With growing revenues and exceptional margins, its price is rising. Its price is already up by 55% over the year, and going by the fact that its P/E is lower than that f...
Summary I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought. The CVR helps to bridge the gap between the price the seller wants and the buyer wants to pay. They are always uniquely structu...
Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook PR Newswire - Peak Annual Net Revenue Potential for SUBLOCADE ® Increased to > $1.5 Billion - Attracti...
Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) is acquiring opioid overdose therapy maker Opiant Pharmaceuticals ( NASDAQ: OPNT ) for ~$145M. North Chesterfield, Va.-based Indivior will acquire all outstanding shares of Opiant for an upfront $20 per share in cash,...
Indivior To Acquire Opiant Pharmaceuticals PR Newswire Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well...
Indivior PLC (INVVY) Q3 2022 Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participants Thibault Boutherin - Morgan Stanley James Vane-Tempest - Jefferies Max Herr...
Indivior PLC ADR press release ( OTCPK:INVVY ): Q3 Non-GAAP EPS of $0.29. Revenue of $232M (+24.1% Y/Y). For further details see: Indivior PLC ADR Non-GAAP EPS of $0.29, revenue of $232M
Indivior Announces Q3 2022 Financial Results PR Newswire SLOUGH, UK and RICHMOND, Va. , Oct. 27, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending September 30, 2022 . The earnings relea...
News, Short Squeeze, Breakout and More Instantly...
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance PR Newswire RICHMOND, Va. , May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation o...
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...